| Ms Patricia A Rice, CRNP | |
|
1562 Opossumtown Pike, Frederick, MD 21702-4337 | |
| (301) 662-8477 | |
| Not Available |
| Full Name | Ms Patricia A Rice |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 34 Years |
| Location | 1562 Opossumtown Pike, Frederick, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023000973 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LA2200X | Nurse Practitioner - Adult Health | R086644 (Maryland) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Frederick Health Medical Group Llc | 9931341096 | 184 |
News Archive
The normal ageing process has long been linked to problems with cell respiration, the process through which the cells extract energy from nutrients. Researchers at the Swedish medical university Karolinska Institutet have now shown how certain proteins that are synthesised in the cellular mitochondria - popularly known as the cells' power plants - become unstable and disintegrate, which in turn can impair cell respiration and cause premature ageing.
A pilot trial to discover whether ginger root can increase metabolic rate and improve circulation in the hands and feet is getting under way at The University of Reading.
London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, has awarded the first three grants from its proof-of-concept (POC) fund. The awards, to teams at Imperial College London and University College London, are for research in the areas of immunotherapy, schizophrenia and heart disease.
New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1
"U.N. officials sounded the alarm Tuesday about a deepening crisis in East Africa, saying they are struggling to cope with the number of people on the move in the region because of the severe drought and continued fighting in Somalia," the Associated Press reports.
› Verified 2 days ago
| Entity Name | Frederick Health Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619258225 PECOS PAC ID: 9931341096 Enrollment ID: O20130820000555 |
News Archive
The normal ageing process has long been linked to problems with cell respiration, the process through which the cells extract energy from nutrients. Researchers at the Swedish medical university Karolinska Institutet have now shown how certain proteins that are synthesised in the cellular mitochondria - popularly known as the cells' power plants - become unstable and disintegrate, which in turn can impair cell respiration and cause premature ageing.
A pilot trial to discover whether ginger root can increase metabolic rate and improve circulation in the hands and feet is getting under way at The University of Reading.
London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, has awarded the first three grants from its proof-of-concept (POC) fund. The awards, to teams at Imperial College London and University College London, are for research in the areas of immunotherapy, schizophrenia and heart disease.
New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1
"U.N. officials sounded the alarm Tuesday about a deepening crisis in East Africa, saying they are struggling to cope with the number of people on the move in the region because of the severe drought and continued fighting in Somalia," the Associated Press reports.
› Verified 2 days ago
| Entity Name | Frederick Health Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Radiation Therapy Center |
| Entity Identifiers | NPI Number: 1891154100 PECOS PAC ID: 0446149256 Enrollment ID: O20160516001434 |
News Archive
The normal ageing process has long been linked to problems with cell respiration, the process through which the cells extract energy from nutrients. Researchers at the Swedish medical university Karolinska Institutet have now shown how certain proteins that are synthesised in the cellular mitochondria - popularly known as the cells' power plants - become unstable and disintegrate, which in turn can impair cell respiration and cause premature ageing.
A pilot trial to discover whether ginger root can increase metabolic rate and improve circulation in the hands and feet is getting under way at The University of Reading.
London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, has awarded the first three grants from its proof-of-concept (POC) fund. The awards, to teams at Imperial College London and University College London, are for research in the areas of immunotherapy, schizophrenia and heart disease.
New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1
"U.N. officials sounded the alarm Tuesday about a deepening crisis in East Africa, saying they are struggling to cope with the number of people on the move in the region because of the severe drought and continued fighting in Somalia," the Associated Press reports.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Patricia A Rice, CRNP Po Box 37086, Baltimore, MD 21297-3086 Ph: (240) 439-8733 | Ms Patricia A Rice, CRNP 1562 Opossumtown Pike, Frederick, MD 21702-4337 Ph: (301) 662-8477 |
News Archive
The normal ageing process has long been linked to problems with cell respiration, the process through which the cells extract energy from nutrients. Researchers at the Swedish medical university Karolinska Institutet have now shown how certain proteins that are synthesised in the cellular mitochondria - popularly known as the cells' power plants - become unstable and disintegrate, which in turn can impair cell respiration and cause premature ageing.
A pilot trial to discover whether ginger root can increase metabolic rate and improve circulation in the hands and feet is getting under way at The University of Reading.
London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, has awarded the first three grants from its proof-of-concept (POC) fund. The awards, to teams at Imperial College London and University College London, are for research in the areas of immunotherapy, schizophrenia and heart disease.
New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1
"U.N. officials sounded the alarm Tuesday about a deepening crisis in East Africa, saying they are struggling to cope with the number of people on the move in the region because of the severe drought and continued fighting in Somalia," the Associated Press reports.
› Verified 2 days ago
Ms. Kimberly Lyn Zeren, CRNP- FAMILY Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 45 Thomas Johnson Dr, Suite 109, Frederick, MD 21702 Phone: 301-696-1011 Fax: 301-696-1520 | |
Ingrid Halvorson, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1562 Opossumtown Pike, Frederick, MD 21702 Phone: 301-662-8477 | |
Issa Tew Lo, CRNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 814 Toll House Ave, Frederick, MD 21701 Phone: 301-662-8310 | |
Kari Pratt, A.R.N.P. Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 87 Thomas Johnson Dr, Ste 101, Frederick, MD 21702 Phone: 301-694-0606 Fax: 301-662-6928 | |
Linda A Cann, MSN,APRN,FNP,PMHNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 226 S Jefferson St, Frederick, MD 21701 Phone: 301-663-6135 Fax: 301-663-5738 | |
Regine Josie, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1026 Bexhill Dr, Frederick, MD 21702 Phone: 321-482-4933 |